Bleomycin electrosclerotherapy for slow-flow vascular malformations
Part of Genetic & congenital, Heart & circulation clinical trials.
This trial tests a treatment called bleomycin electrosclerotherapy for people with slow-flow vascular malformations (abnormal blood vessels that do not flow quickly). The goal is to see if this treatment works well and is safe for these conditions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be scheduled to have this treatment as part of your regular medical care.
- You must have a diagnosis of a slow-flow vascular malformation that was confirmed by an MRI with contrast within the last 6 months.
- You have not had any invasive treatment for your vascular malformation in the last 6 months, such as surgery, sclerotherapy, or laser treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment called bleomycin electrosclerotherapy (BEST) for low-flow vascular malformations—abnormal blood vessel or lymph vessel growths that haven't responded well to previous treatments. The treatment involves injecting bleomycin (a medication) directly into the malformation and using electrical current to help destroy it.
This study is testing a treatment called electrosclerotherapy for low-flow venous malformations. It uses a medicine (bleomycin) injected into the abnormal blood vessels to shrink them. The goal is to see how well it works and how safe it is.
This trial tests two targeted medicines for people with certain types of vascular malformations (abnormal blood vessels). If you have a slow-flow malformation, you may receive alpelisib; if you have a fast-flow malformation, you may receive mirdametinib. Genetic testing is needed to see if your malformation has a specific change that these drugs target.
This trial tests if microwave ablation can safely treat painful or bothersome vascular malformations (abnormal blood vessel clusters). It helps people who have symptoms like pain, swelling, or ulcers that need treatment.
This trial tests the drug everolimus for people with certain types of vascular anomalies (tumors or malformations in blood vessels) that have not improved with other treatments. It aims to see if everolimus can help shrink these growths or control their symptoms.
This Phase 3 study tests whether sirolimus helps control complex vascular anomalies that have not responded to standard treatments. It also checks safety by monitoring blood tests, organ function, and overall health during treatment.
Hear when a new Vascular Malformations trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.